Azeliragon

DRUG9 trials

Conditions

Alzheimer DiseaseAlzheimer's DiseaseBrain MetastasesBrain Metastases, AdultCOVID-19CancerGlioblastomaHigh-grade Glioma

Early Phase 1

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

RecruitingNCT06831526

Washington University School of MedicineGlioblastoma

Start: 2025-11-06End: 2030-08-31Target: 12Updated: 2025-11-12

Phase 1

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

RecruitingNCT05766748

Cantex PharmaceuticalsMetastatic Pancreatic Cancer

Start: 2023-06-01End: 2025-05-31Target: 30Updated: 2024-06-14

Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma

WithdrawnNCT05773664

City of Hope Medical CenterGlioblastoma, Malignant Glioma

Start: 2024-11-15End: 2024-11-29Updated: 2024-09-19

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

RecruitingNCT05789589

Baptist Health South FloridaBrain Metastases, Brain Metastases, Adult, Cancer +2

Start: 2023-11-17End: 2027-08-01Target: 46Updated: 2026-03-04

Concurrent Azeliragon With Craniospinal Irradiation

RecruitingNCT06724926

NYU Langone HealthHigh-grade Glioma, Leptomeningeal Metastasis, Solid Tumor

Start: 2025-02-18End: 2031-01-31Target: 32Updated: 2026-01-02

Phase 2

Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

TerminatedNCT03980730

vTv TherapeuticsAlzheimer Disease

Start: 2019-06-27End: 2021-01-29Updated: 2022-01-21

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

Active, not recruitingNCT05815485

The University of Texas Medical Branch, GalvestonCOVID-19

Start: 2023-05-04End: 2026-04-30Target: 144Updated: 2025-03-03

Azeliragon in MGMT Unmethylated Glioblastoma

Active, not recruitingNCT05986851

Cantex PharmaceuticalsGlioblastoma

Start: 2023-09-12End: 2026-12-30Updated: 2026-03-31

Phase 3

Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease

TerminatedNCT02080364

vTv TherapeuticsAlzheimer's Disease

Start: 2015-04-30End: 2018-06-01Updated: 2021-05-07

Neuro-Oncology2025-11-01

CTIM-04. A PHASE II STUDY OF AZELIRAGON IN COMBINATION WITH RADIATION THERAPY IN NEWLY DIAGNOSED PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA

Neuro-Oncology2025-11-01

CTLT-04 SAFETY AND PRELIMINARY EVIDENCE OF A THERAPEUTIC EFFECT OF AZELIRAGON COMBINED WITH STEREOTACTIC RADIATION THERAPY IN PATIENTS WITH BRAIN METASTASES: PHASE 1 STUDY RESULTS

Neuro-Oncology Advances2025-08-01

A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION).

Journal of Clinical Oncology2025-05-28

S100A proteins show a spatial distribution of inflammation associated with the glioblastoma microenvironment architecture

Theranostics2024-12-026 citations

CTIM-26. PHASE II STUDY OF AZELIRAGON IN COMBINATION WITH RADIATION THERAPY IN NEWLY DIAGNOSED PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA

Neuro-Oncology2024-11-01

A phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer.

Journal of Clinical Oncology2024-06-011 citations

A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION).

Journal of Clinical Oncology2024-06-01

Transcranial Electromagnetic Treatment “Rebalances” Blood and Brain Cytokine Levels in Alzheimer’s Patients: A New Mechanism for Reversal of Their Cognitive Impairment

Frontiers in Aging Neuroscience2022-05-0216 citations